San Francisco, 24 April 2030: The Report India Large Volume Parenteral Market Size, Share & Trends Analysis Report By Application (Therapeutic Injections, Fluid Balance Injections, Nutritious Injections), By Volume, By End-use, And Segment Forecasts, 2023 - 2030

The India large volume parenteral market size is expected to reach USD 146.2 billion by 2030, expanding at a CAGR of 5.3% from 2023 to 2030, according to a new report by Grand View Research, Inc. Large Volume Parenteral (LVP) injections are used for either total or partial nutrition when oral intake is insufficient or challenging. Earlier, these formulations were used for patients undergoing surgical procedures or those admitted to a hospital.

Currently, they are used as substitutes for nutrition obtained from a healthy diet. However, the demand for LVPs has significantly increased due to the growing adoption of parenteral nutrition over enteral nutrition among COVID-19 patients for improving drug absorption, shorter hospital stays, and reduced risk of infections. This is anticipated to drive the market over the forecast period.

In 2020, the nutritious injections application segment accounted for the largest revenue share. This is attributed to the growing adoption of these products in delivering intravenous carbohydrates, amino acids, electrolytes, and minerals to meet adequate nutritional requirements when enteral nutrition mode is insufficient, not possible, or contraindicated. On the other hand, the therapeutic injections segment is anticipated to register the fastest growth during the forecast period. The increasing prevalence of chronic conditions, such as cancer, can significantly impact the adoption of LVPs in the country, as they can provide vital nutrients to help maintain strength, energy, and hydration in patients from diagnosis to recovery.

In 2020, the 500 ml volume segment accounted for the largest revenue share. The increasing number of ICU admissions, rising demand for parenteral formulation among critically ill patients, growing preference for single-dose administration of vaccines and drugs, and increasing prevalence of various chronic disorders such as cancer and diabetes are some of the factors expected to propel this segment. On the other hand, the 100 ml volume segment is anticipated to register the fastest growth during the forecast period, as it can help avoid adverse effects related to nutrition and electrolyte imbalances.

In 2020, the hospital and other healthcare facilities segment dominated the market. The segment is anticipated to maintain its dominance during the forecast period. The growing prevalence of chronic conditions requiring dietary management in patients and increasing incidence of hospital-acquired malnutrition are expected to boost demand for LVPs. In addition, these formulations are administered preoperatively to reduce the rate of complications and hospital stay among surgical ICU patients. This is likely to increase the demand for LVPs among surgical and intensive care patients, thereby, propelling segment growth.

Request sample report of India Large Volume Parenteral Market@ https://www.grandviewresearch.com/industry-analysis/india-large-volume-parenteral-lvp-market/request/rs1

An increase in local manufacturing of Large Volume Parenteral (LVP) is contributing to the growth of the market in India. The presence of many malnourished children, high natality, increasing rate of premature births, growing prevalence of cancer, and rising adoption of LVP formulations in various healthcare and home care settings for chronically ill geriatric patients are factors expected to drive the market.

Diseases such as Crohn’s, esophageal cancer, ulcerative colitis, gastric cancer, head and neck cancer, and laryngeal cancer can affect the oral intake of food in patients. Their growing prevalence is, in turn, expected to drive the demand for the parenteral mode of drug administration, aiding the growth of the market for large volume parenteral. For instance, according to the Global Cancer Observatory (GLOBCON) 2020 report, India had 60,222 new cases of gastric cancer, and it caused around 53,253 deaths.

The benefits offered by parenteral formulations, including lower postoperative inflammatory response, lower infection rates, improved postsurgical immune competence, adequate nutrient supply, and shorter hospital stays, positively impact market growth. LVPs provide a faster method for drug administration for patients during surgery or while recovering in the hospital. Growing physician preference for single-dose administration of vaccines and drugs to treat chronic diseases is further driving the demand for LVPs. The market is expanding due to an increase in the number of surgeries performed and the growing number of patients with chronic and lifestyle diseases that require hospitalization. For instance, according to the Department of Biotechnology of the Government of India (GOI), non-communicable diseases are responsible for 53% of overall deaths and 44% of disability-adjusted life years lost in the country. Moreover, India has around 77 million people living with diabetes, which is estimated to reach 134 million by 2045.

The COVID-19 pandemic has positively impacted market growth owing to an increase in the adoption of LVPs for various applications and an increase in physician’s preference towards single-dose drug administration for improving drug absorption and faster and safer patient recovery. In addition, the rising prevalence of chronic diseases and malnutrition and rapid growth in the geriatric population are driving the adoption of LVPs. For instance, according to Feeding India, in December 2022, India is the largest contributor to malnutrition globally with around 194.4 million people being undernourished. Moreover, India has the highest rate of child malnutrition, as 1 in every 3 malnourished children in the world is Indian. In addition, the increasing number of surgical procedures and the presence of critically ill patients with hampered physiological functioning of the enteral route are additional factors surging the adoption of parenteral nutrition as an alternate route of administration.

Severe malnutrition in pregnant women is associated with intrauterine growth restriction, preterm delivery, congenital malformations, low birth weight, and perinatal mortality. Parenteral nutrition is advisable for pregnant women whose nutritional requirements are not fulfilled by enteral intake. Moreover, the adoption of LVPs as part of total parenteral nutrition is increasing for pregnant women to help maintain or restore optimal nutritional status for the mother as well as the fetus when caloric intake by oral or enteral routes is not sufficient. In addition, it provides necessary nutritional requirements for fulfilling metabolic and anabolic needs without increasing the overall risk of complications. Thus, the country's high natality and birth rate are further expected to propel the market growth. According to the United Nations (UN) World Population Prospect 2023, India has the highest number of births globally, with around 24 million births every year.

The Indian government has undertaken many steps to reduce medical costs and healthcare expenditures. The rapid introduction of generic drugs in the market for large-volume parenteral has remained a major focus and is expected to benefit Indian pharmaceutical companies. The companies are adopting new business models and introducing innovative ideas to meet consumer expectations. Indian pharma companies may continue to grow organically and inorganically through acquisitions and partnerships, which, in turn, drive the market. For instance, in November 2020, Grifols and B Braun SE formed an alliance to enhance therapy safety and pharmacy production output. Grifols’ Kiro and B Braun SE’s Safe Infusion Systems will be combined to provide solutions for safe automated drug mixtures and delivery systems.